Tazorac

PreclinicalSmall molecule

FFougera Pharmaceuticals Inc.

Tazorac is one of 8 small molecule programs targeting Actinic Keratoses. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Actinic KeratosesCompleted

ToleranceCompleted

Actinic KeratosesPreclinical

Completed

TolerancePreclinical

Completed

Competition

Competitive Landscape

9 competitors in Tolerance

#DrugCompanyPhaseTrials

Avigan

AAppili Therapeutics Inc.

Phase 2

2 2

Experimental

Biogen

Preclinical

1 3

Levo-Dromoran

VValeant Pharmaceuticals

Preclinical

1 4

Siplizumab

UUniversity of Alabama at Birmingham

Preclinical

—5

Tazorac

FFougera Pharmaceuticals Inc.

Preclinical

1 6

Oxytocin Treatment

UUniversity of Electronic Science and Technology of China

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis3 trials

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Completed·FFougera Pharmaceuticals Inc.·Phase 3·NCT02886702·855 enrolled

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

Completed·BBausch Health Americas, Inc.·Phase 1·NCT03058744·94 enrolled

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Completed·BBausch Health Americas, Inc.·Phase 2·NCT02785159·152 enrolled

Acne Vulgaris2 trials

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Completed·FFougera Pharmaceuticals Inc.·Phase 3·NCT02886715·1,110 enrolled

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Completed· Sun Pharmaceutical Industries, Inc. logo

Sun Pharmaceutical Industries, Inc.·Phase 1·NCT02411955·1,077 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

Completed·—·Phase 4·NCT00648986·20 enrolled

Tolerance1 trial

The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance

Completed·UUniversity of Michigan·N/A·NCT00440024·40 enrolled

Actinic Keratoses1 trial

Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses

Completed·SStewart, Roger H., M.D., P.A.·N/A·NCT01053000·10 enrolled

2 more indications

Safety and Efficacy1 trial

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Completed·BBausch Health Americas, Inc.·Phase 2·NCT02938494·210 enrolled

Absorption1 trial

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Completed·BBausch Health Americas, Inc.·Phase 1·NCT02849873·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Tazorac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tazorac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tazorac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fougera Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFougera Pharmaceuticals Inc.

Tazorac

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis3 trials

Acne Vulgaris2 trials

Efficacy and Safety1 trial

Tolerance1 trial

Actinic Keratoses1 trial

Safety and Efficacy1 trial

Absorption1 trial

References

Drug Info

Quick Facts

Related News